Plus Therapeutics, Inc. (PSTV) — DEF 14A Filings
All DEF 14A filings from Plus Therapeutics, Inc.. Browse 3 Proxy Statement reports with AI-powered summaries and risk analysis.
DEF 14A Filings (3)
-
PLUS THERAPEUTICS Advances Cancer Pipeline, Bolstered by CNSide Acquisition
— Jul 21, 2025 Risk: medium
PLUS THERAPEUTICS, INC. (PSTV) has made significant strides in its radiotherapeutic pipeline and expanded its portfolio with the mid-2024 acquisition of CNSide® -
Plus Therapeutics Files Definitive Proxy Statement
— Apr 10, 2025 Risk: low
Plus Therapeutics, Inc. filed its definitive proxy statement on April 10, 2025, for its annual meeting of stockholders. The filing, under the 1934 Securities Ex -
Plus Therapeutics Files Definitive Proxy Statement
— Jul 10, 2024 Risk: medium
Plus Therapeutics, Inc. filed a definitive proxy statement on July 10, 2024, for its annual meeting of stockholders scheduled for August 15, 2024. The company,
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX